7/29/2019 Drug Study TB

1/5

NAME OF

THE

DRUG

DOSE/

ROUTE

INDICATION

ACTION

SIDE

EFFECTS

NURSES

RESPONSIBILITY

Isoniazid

(INH)

Antituberc

ulars

300 mg

daily

First-line therapy of

active tuberculosis, in

com- bination with

other agents.

Prevention of

tuberculosis in patients

exposed to active

disease (alone).

Bacteriocidal against

rapidly dividing cells

Asymptomatic

elevation of

aminotransferas

es, clinical

hepatitis,

fulminant

hepatitis,

peripheral

neurotoxicity,

hypersensitivity

(skin rash,

arthralgia,

fever)

Mycobacterial studies andsusceptibility tests should be

performed prior to and

periodically throughout therapy

to detect possible resistance.

Hepatic function should beevaluated prior to and monthly

throughout therapy.

Advice patient to takemedication exactly as directed.if

a dose is missed take as soon as

possible.

Emphasize the importance ofcontinuing therapy even after

symptoms have subsided.

Advice patient to notify healthcare professional promptly if

signs and symptoms of hepatitis.

Caution patient to avoid the useof alcohol during the therapy

7/29/2019 Drug Study TB

2/5

Rifampin

(Rifadin)

Antituberc

ular.

600mg/d

ay

Active tuberculosis

(with other agents).

Elimination of

meningococcal

carriers.

Bacteriocidal against

rapidly dividing cells and

against semidormant

bacteria

Cutaneous

reactions, GI

disturbance

(nausea,

anorexia,

abdominal

pain), flulike

syndrome,

hepatotoxicity,

immunologic

reactions,

orange

discoloration of

bodily fluids

(sputum, urine,

sweat, tears);

drug

interactions

Perform mycobacterial studiesand susceptibility test prior to

and periodically during therapy

to detect possible resistance.

Assess lung sound and characterand amount of sputum

periodically during therapy.

Evaluate renal function, CBC,and urine analysis periodically.

Monitor LFT.

7/29/2019 Drug Study TB

3/5

Ethambutol

(Myambutol)

antituberc

ular

1 gm

daily

Active tuberculosis or

other mycobacterial

disease.

Bacteriostatic for the

tubercle bacillusRetrobulbar

neuritis

(decreased red-

green color

discrimination),peripheral

neuritis (rare),

skin rash

Evaluate renal function, CBC,and urine analysis periodically.

Monitor LFT. Hepatic function should be

evaluated prior to and monthly

throughout therapy.

Advice patient to takemedication exactly as directed.if

a dose is missed take as soon as

possible.

7/29/2019 Drug Study TB

4/5

DRUG NAME DOSE &

ROUTE

ACTION INDICATIONS SIDE-EFFECTS NURSING

RESPONSIBILITIES

Pyrazinamide

(PZA)1 gm daily

Oral

Bacteriocidal effect

against dormant or

semidormant organisms

Used in combination

with other agents in the

treatment of active

tuberculosis.

Hepatotoxicity, GI

symptoms (nausea,

vomiting),

polyarthralgias,

skin rash,

hyperuricemia,

dermatitis

Emphasize the importanceof continuing therapy

even after symptoms havesubsided.

Advice patient to notifyhealth care professional

promptly if signs and

symptoms of hepatitis.

Caution patient to avoidthe use of alcohol during

the therapy

Hepatic function shouldbe evaluated prior to and

monthly throughout

therapy.

Advice patient to takemedication exactly as

directed.

7/29/2019 Drug Study TB

5/5

NAME OF

THE

DRUG

DOSE/

ROUTE

INDICATION

ACTION

SIDE

EFFECTS

NURSES

RESPONSIBILITY

tab.rantac

(h2

antagonists)

150mg

BD

Oral

Short-term treatment

of active duodenal

ulcers and benign

gastric ulcers.

Maintenance therapy

for duodenal and

gastric ulcers after

healing of

active ulcers.

Management of

GERD. Treatment of

heartburn, acid

indigestion.

H2 receptor antagonist, it

blokes the histamine h2

receptors , and prevents

histamine mediated gastric

acid secretion

-none reported,

other: headache,

dizziness, rarely

hepatitis,

confusion,

hypersensitivity

Assess for epigastric orabdominal pain and frank or

occult blood in the stool,

emesis, or gastric aspirate.

-it should be given in emptystomach.

Watch for any allergicreaction